Skip to content
stoqly
en

Popular

All languages

Figures come from SEC filings, which are in English. Company and industry names stay as filed.

$ USD

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 23, 2026.

Acumen Pharmaceuticals, Inc.

ABOS Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2020โ€“FY2025

Last close ยท Oct 23, 2026

$1.98

3.9%
Compare
Revenue Total sales reported in the income statement.
โ€”
vs prior year
Operating margin Operating income as a share of revenue.
โ€”
Net income Profit after all expenses, interest and tax.
โˆ’$121M
Free cash flow Cash from operations minus capital spending.
โˆ’$116M
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
โ€”
Market cap Last close times the latest diluted share count, so it is approximate.
$143M
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
โ€”
On โˆ’$1.62 EPS (TTM)

What Acumen Pharmaceuticals, Inc. does

No business description yet.

Legal name
Acumen Pharmaceuticals, Inc.
Fiscal year ends
December 31, 2025
Latest annual report
10-K ยท Mar 26, 2026
Accession ยท CIK
0001628280-26-021413
0001576885

Revenue and margins

Acumen Pharmaceuticals, Inc. had โ€” of revenue in fiscal 2025.

Revenue
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was โˆ’$116M in fiscal 2025, โ€” of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Acumen Pharmaceuticals, Inc. returned โ€” to shareholders in fiscal 2025. The diluted share count rose 0.9%.

Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Balance sheet

Cash, debt and the ratios that show how comfortably Acumen Pharmaceuticals, Inc. can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $194M$178M$244M$172M$117M
Debt incl. finance leases โ€”$0.0M$30.7M$29.4M$31.2M
Debt / equity โ€”0.0x0.1x0.2x0.4x
Interest coverage โ€”โ€”โˆ’105.2xโˆ’28.0xโˆ’29.3x
Current ratio 38.6x23.1x19.0x6.5x4.1x
Quick ratio 38.6x23.1x19.0x6.5x4.1x
Total assets $230M$197M$310M$239M$123M
Total liabilities $5.1M$7.8M$43.2M$57.2M$52.4M
Shareholders' equity $225M$189M$267M$182M$70.4M
Net debt (โˆ’ = net cash) โ€”โˆ’$178Mโˆ’$213Mโˆ’$142Mโˆ’$85.7M

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โ€œPlanโ€ marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

โ€”

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8โ€“9 is strong, 0โ€“2 weak.

TestFY20FY21FY22FY23FY24FY25
Net income is positive โœ• โœ• โœ• โœ• โœ• โœ•
Cash from operations is positive โœ• โœ• โœ• โœ• โœ• โœ•
Return on assets rose โ€” โœ• โœ“ โœ“ โœ• โœ•
Cash from operations exceeds net income โœ• โœ“ โœ“ โœ“ โœ“ โœ“
Debt fell relative to assets โ€” โ€” โ€” โœ• โœ• โœ•
Current ratio rose โ€” โ€” โœ• โœ• โœ• โœ•
Share count didn't rise โ€” โœ• โœ• โœ• โœ• โœ•
Gross margin rose โ€” โ€” โ€” โ€” โ€” โ€”
Revenue rose relative to assets โ€” โ€” โ€” โ€” โ€” โ€”
F-score โ€” / 3โ€” / 5โ€” / 62 / 71 / 71 / 7
Accruals ratio 0.3%โˆ’60.2%โˆ’3.6%โˆ’3.7%โˆ’5.9%โˆ’3.2%
Altman Z'' โ€”49.0726.767.77โˆ’0.17โˆ’12.29

6 years of figures

Amounts in USD. Hover a ratioโ€™s name for its definition.

Download CSV
Fiscal yearFY20FY21FY22FY23FY24FY25
Income statement
Research and development $8.0M $12.3M $32.4M $42.3M $93.8M $105M
Operating income โˆ’$7.9M โˆ’$19.6M โˆ’$45.2M โˆ’$61.1M โˆ’$114M โˆ’$124M
Interest expense โ€” โ€” $0.0M $0.6M $4.1M $4.2M
Income tax $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Net income โˆ’$7.3M โˆ’$101M โˆ’$42.9M โˆ’$52.4M โˆ’$102M โˆ’$121M
Diluted EPS โˆ’$17.48 โˆ’$5.02 โˆ’$1.06 โˆ’$1.08 โˆ’$1.71 โˆ’$2.00
Diluted shares 0.00B 0.02B 0.04B 0.05B 0.06B 0.06B
Cash flow
Cash from operations โˆ’$7.5M โˆ’$18.0M โˆ’$35.2M โˆ’$43.1M โˆ’$86.2M โˆ’$116M
Capital expenditure โ€” $0.0M $0.2M $0.0M $0.0M $0.1M
Free cash flow โ€” โˆ’$18.0M โˆ’$35.3M โˆ’$43.1M โˆ’$86.2M โˆ’$116M
Depreciation and amortization โ€” $0.0M $0.0M $0.1M $0.1M $0.1M
Stock-based compensation $0.2M $0.9M $3.1M $6.1M $9.6M $9.9M
Balance sheet
Cash and short-term investments $43.8M $194M $178M $244M $172M $117M
Total debt โ€” โ€” $0.0M $29.9M $29.4M $31.2M
Finance lease liabilities โ€” โ€” โ€” $0.8M โ€” โ€”
Current assets $44.4M $199M $180M $247M $178M $122M
Current liabilities โ€” $5.1M $7.8M $13.0M $27.6M $30.0M
Property and equipment, net โ€” $0.0M $0.2M $0.1M $0.1M $0.1M
Total assets $44.4M $230M $197M $310M $239M $123M
Total liabilities $6.4M $5.1M $7.8M $43.2M $57.2M $52.4M
Preferred stock โ€” $0.0M $0.0M $0.0M $0.0M $0.0M
Shareholders' equity โˆ’$18.6M $225M $189M $267M $182M $70.4M
Returns
Return on capital โ€” โ€” โˆ’319.9% โˆ’90.5% โˆ’227.0% โ€”
Return on capital employed โ€” โˆ’8.7% โˆ’24.0% โˆ’20.6% โˆ’53.9% โˆ’133.4%
Return on equity โ€” โˆ’97.4% โˆ’20.7% โˆ’23.0% โˆ’45.6% โˆ’96.2%
Return on assets โˆ’16.5% โˆ’73.2% โˆ’20.1% โˆ’20.7% โˆ’37.3% โˆ’67.1%
Return on tangible equity โ€” โˆ’44.7% โˆ’22.7% โˆ’19.6% โˆ’56.3% โˆ’172.3%
Growth
Share count change โ€” 4,685.9% 102.4% 19.7% 23.5% 0.9%
Financial health
Debt / equity โ€” โ€” 0.0x 0.1x 0.2x 0.4x
Interest coverage โ€” โ€” โ€” โˆ’105.2x โˆ’28.0x โˆ’29.3x
Current ratio โ€” 38.6x 23.1x 19.0x 6.5x 4.1x
Quick ratio โ€” 38.6x 23.1x 19.0x 6.5x 4.1x
Quality scores
Piotroski F-score โ€” โ€” โ€” 2.0 1.0 1.0
Altman Z'' โ€” 49.1 26.8 7.8 โˆ’0.2 โˆ’12.3
Accruals ratio 0.3% โˆ’60.2% โˆ’3.6% โˆ’3.7% โˆ’5.9% โˆ’3.2%

Source: SEC EDGAR XBRL filings (CIK 0001576885). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ€” not investment advice. Check the original filings before relying on any figure.

โ†‘ โ†“ to move ยท โ†ต to open